Please use this identifier to cite or link to this item: https://repositorio.ufrn.br/jspui/handle/123456789/23909
Title: Nanostructured transdermal hormone replacement therapy for relieving menopausal symptoms: a confocal Raman spectroscopy study
Authors: Botelho, Marco Antonio
Queiroz, Dinalva Brito
Barros, Gisele
Guerreiro, Stela
Fechine, Pierre
Umbelino, Sonia
Lyra, Arão
Borges, Boniek Castillo Dutra
Freitas, Allan
Queiroz, Danilo Caldas de
Ruela, Ronaldo
Almeida, Jackson Guedes
Quintans Junior, Lucindo
Keywords: Nanotechnology;Confocal raman spectroscopy;Transdermal delivery;Menopause;Hormone therapy;Nanoparticles
Issue Date: 2014
Citation: BOTELHO, Marco Antonio. Nanostructured transdermal hormone replacement therapy for relieving menopausal symptoms: a confocal Raman spectroscopy study. Clinics, v. 69, n. 2, p. 75-82, 2014.
Portuguese Abstract: OBJECTIVE: To determine the safety and efficacy of a transdermal nanostructured formulation of progesterone (10%) combined with estriol (0.1%) + estradiol (0.25%) for relieving postmenopausal symptoms. METHODS: A total of 66 postmenopausal Brazilian women with climacteric symptoms of natural menopause received transdermal nanostructured formulations of progesterone and estrogens in the forearm daily for 60 months to mimic the normal ovarian secretory pattern. Confocal Raman spectroscopy of hormones in skin layers was performed. Clinical parameters, serum concentrations of estradiol and follicle-stimulating hormone, blood pressure, BI-RADS classification from bilateral mammography, and symptomatic relief were compared between baseline and 60 months post-treatment. Clinicaltrials.gov: NCT02033512. RESULTS: An improvement in climacteric symptoms was reported in 92.5% of women evaluated before and after 60 months of treatment. The serum concentrations of estradiol and follicle-stimulating hormone changed significantly (p<0.05) after treatment; the values of serum follicle-stimulating hormone decreased after 60 months from 82.04±4.9 to 57.12±4.1 IU/mL. A bilateral mammography assessment of the breasts revealed normal results in all women. No adverse health-related events were attributed to this hormone replacement therapy protocol. CONCLUSION: The nanostructured formulation is safe and effective in re-establishing optimal serum levels of estradiol and follicle-stimulating hormone and relieving the symptoms of menopause. This transdermal hormone replacement therapy may alleviate climacteric symptoms in postmenopausal women.
URI: https://repositorio.ufrn.br/jspui/handle/123456789/23909
Appears in Collections:CCS - DOD - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
Nanostructured transdermal hormone replacement therapy for relieving.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912337/2,83 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.